SNGX - Wutah pendapatan taunan sajrone rolas wulan kepungkur soligenix.com

Logo grafis Soligenix (SNGX)

Geopolitical tensions and bio-threats are driving government orders for anti-infective agents, providing Soligenix, Inc. (SNGX) with stability. U.S. grants support the firm's resilience, although success depends on clinical trial outcomes. Revenues are based on therapies for rare pathologies and radiation protection, while the TTM revenue growth YoY captures the actual pace of expansion, and 0.00 marks a new level.

Wutah dodolan YoY sajrone rolas wulan kepungkur soligenix.com (SNGX): kanggo periode 11.02.2024 - 17.11.2026

Ringkesan rincian data analitis soligenix.com (SNGX)

- rega saiki lan proyeksi nilai saham:
Analisis kabeh metrik perusahaan:Soligenix, Inc.
Produk mawa merek Soligenix, Inc.

Revenue dynamics determine the fundamental resilience of the business amid inflationary pressures. This indicator measures the percentage change in sales volume over the last twelve months, allowing for the rapid detection of stagnation prior to the publication of financial statements. By analyzing this TTM annual sales growth chart, an investor assesses the company's real expansion. For Soligenix, Inc. (SNGX), this trend is critical as it reflects the competitiveness of its drugs against the expansion of pharmaceutical behemoths. Sales growth confirms the issuer's market niche in the struggle against larger players.